Magnetic nanoparticles enhance the anticancer activity of cathelicidin LL-37 peptide against colon cancer cells

International Journal of Nanomedicine

Volumn 10, Issue , 2015, Pages 3843-3853

  Niemirowicz, Katarzyna ^a   Prokop, Izabela ^a   Wilczewska, Agnieszka Z ^b   Wnorowska, Urszula ^a   Piktel, Ewelina ^a   Wątek, Marzena ^c   Savage, Paul B ^d   Bucki, Robert ^a,e  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b UNIVERSITY OF BIALYSTOK   (Poland)

^c Center Holy Cross Regional Hospital   (Poland)

^d Brigham Young University   (United States)

^e JAN KOCHANOWSKI UNIVERSITY   (Poland)

Author keywords

Anticancer activity; Cathelicidin LL 37; Ceragenin; Colorectal cancer; Magnetic nanoparticles

Indexed keywords

CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CERAGENIN CSA 13; MAGNETIC NANOPARTICLE; POLYPEPTIDE ANTIBIOTIC AGENT; UNCLASSIFIED DRUG; ANTIMICROBIAL CATIONIC PEPTIDE; ANTINEOPLASTIC AGENT; CAP18 LIPOPOLYSACCHARIDE-BINDING PROTEIN; CERAGENIN CSA-13; MAGNETITE NANOPARTICLE; STEROID;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CELL LINE; CANCER INHIBITION; CELL VIABILITY; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DLD 1 CELL LINE; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG MECHANISM; DRUG SCREENING; DRUG SYNTHESIS; DRUG TRANSPORT; HT 29 CELL LINE; IN VITRO STUDY; INTERNALIZATION; NANOMEDICINE; NANOPHARMACEUTICS; CELL SURVIVAL; CHEMISTRY; COLONIC NEOPLASMS; DRUG EFFECTS; HT-29 CELL LINE; HUMAN; PROCEDURES; THERANOSTIC NANOMEDICINE; TUMOR CELL LINE;

ANTIMICROBIAL CATIONIC PEPTIDES; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; COLONIC NEOPLASMS; HT29 CELLS; HUMANS; MAGNETITE NANOPARTICLES; STEROIDS; THERANOSTIC NANOMEDICINE;

EID: 84933508997     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S76104     Document Type: Article

References (39)

1. Sørensen OE, Follin P, Johnsen AH, et al. Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood. 2001;97(12):3951–3959.
2. Bals R, Wilson JM. Cathelicidins – a family of multifunctional antimicrobial peptides. Cell Mol Life Sci. 2003;60(4):711–720.
3. Leszczynska K, Namiot D, Byfeld FJ, et al. Antibacterial activity of the human host defence peptide LL-37 and selected synthetic cationic lipids against bacteria associated with oral and upper respiratory tract infections. J Antimicrob Chemother. 2013;68(3):610–618.
4. Bucki R, Leszczyńska K, Namiot A, Sokołowski W. Cathelicidin LL-37: a multitask antimicrobial peptide. Arch Immunol Ther Exp (Warsz). 2010;58(1):15–25.
5. Dorschner RA, Pestonjamasp VK, Tamakuwala S, et al. Cutaneous injury induces the release of cathelicidin anti-microbial peptides active against group A Streptococcus. J Invest Dermatol. 2001;117(1):91–97.
6. Sawa T, Kurahashi K, Ohara M, et al. Evaluation of antimicrobial and lipopolysaccharide-neutralizing effects of a synthetic CAP18 fragment against Pseudomonas aeruginosa in a mouse model. Antimicrob Agents Chemother. 1998;42(12):3269–3275.
7. Coffelt SB, Marini FC, Watson K, et al. The pro-infammatory peptide LL-37 promotes ovarian tumor progression through recruitment of mul-tipotent mesenchymal stromal cells. Proc Natl Acad Sci U S A. 2009; 106(10):3806–3811.
8. Hensel JA, Chanda D, Kumar S, et al. LL-37 as a therapeutic target for late stage prostate cancer. Prostate. 2011;71(6):659–670.
9. Koczulla R, von Degenfeld G, Kupatt C, et al. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest. 2003; 111(11):1665–1672.
10. Salvado MD, Di Gennaro A, Lindbom L, Agerberth B, Haeggström JZ. Cathelicidin LL-37 induces angiogenesis via PGE2-EP3 signaling in endothelial cells, in vivo inhibition by aspirin. Arterioscler Thromb Vasc Biol. 2013;33(8):1965–1972.
11. Aarbiou J, Tjabringa GS, Verhoosel RM, et al. Mechanisms of cell death induced by the neutrophil antimicrobial peptides alpha-defensins and LL-37. Infamm Res. 2006;55(3):119–127.
12. Kuroda K, Fukuda T, Okumura K, et al. Ceragenin CSA-13 induces cell cycle arrest and antiproliferative effects in wild-type and p53 null mutant HCT116 colon cancer cells. Anticancer Drugs. 2013;24(8):826–834.
13. Kuroda K, Fukuda T, Yoneyama H, et al. Anti-proliferative effect of an analogue of the LL-37 peptide in the colon cancer derived cell line HCT116 p53+/+ and p53-/-. Oncol Rep. 2012;28(3): 829–834.
14. Lai XZ, Feng Y, Pollard J, et al. Ceragenins: cholic acid-based mimics of antimicrobial peptides. Acc Chem Res. 2008;41(10):1233–1240.
15. Surel U, Niemirowicz K, Marzec M, Savage PB, Bucki R. Ceragenins – a new weapon to fght multidrug resistant bacterial infections. Studia Medyczne. 2014;30(3):207–213.
16. Okumura K, Itoh A, Isogai E, et al. C-terminal domain of human CAP18 antimicrobial peptide induces apoptosis in oral squamous cell carcinoma SAS-H1 cells. Cancer Lett. 2004;212(2):185–194.
17. Wu WK, Wang G, Coffelt SB, et al. Emerging roles of the host defense peptide LL-37 in human cancer and its potential therapeutic applications. Int J Cancer. 2010;127(8):1741–1747.
18. Coffelt SB, Waterman RS, Florez L, et al. Ovarian cancers overex-press the antimicrobial protein hCAP-18 and its derivative LL-37 increases ovarian cancer cell proliferation and invasion. Int J Cancer. 2008;122(5):1030–1039.
19. Heilborn JD, Nilsson MF, Jimenez CI, et al. Antimicrobial protein hCAP18/LL-37 is highly expressed in breast cancer and is a putative growth factor for epithelial cells. Int J Cancer. 2005;114(5):713–719.
20. Huang C, Tang Z, Zhou Y, et al. Magnetic micelles as a potential platform for dual targeted drug delivery in cancer therapy. Int J Pharm. 2012;429(1–2):113–122.
21. Wilczewska AZ, Niemirowicz K, Markiewicz KH, Car H. Nanoparticles as drug delivery systems. Pharmacol Rep. 2012;64(5):1020–1037.
22. Wang X, Liu H, Chen D, et al. Multifunctional Fe3O4@P(St/MAA)@ chitosan@Au core/shell nanoparticles for dual imaging and photother-mal therapy. ACS Appl Mater Interfaces. 2013;5(11):4966–4971.
23. Barick KC, Singh S, Bahadur D, Lawande MA, Patkar DP, Hassan PA. Carboxyl decorated Fe3O4 nanoparticles for MRI diagnosis and localized hyperthermia. J Colloid Interface Sci. 2014;418:120–125.
24. Liu Y, Feng L, Liu T, et al. Multifunctional pH-sensitive polymeric nanoparticles for theranostics evaluated experimentally in cancer. Nanoscale. 2014;6(6):3231–3242.
25. Matsushita H, Mizukami S, Sugihara F, Nakanishi Y, Yoshioka Y, Kikuchi K. Multifunctional core–shell silica nanoparticles for highly sensitive (19) f magnetic resonance imaging. Angew Chem Int Ed Engl. 2014;53(4):1008–1011.
26. Niemirowicz K, Swiecicka I, Wilczewska AZ, et al. Gold-functionalized magnetic nanoparticles restrict growth of Pseudomonas aeruginosa. Int J Nanomedicine. 2014;9:2217–2224.
27. Stober, W, Fink, A and Bohn E. Controlled Growth of Monodisperse Silica Spheres in the Micron Size Range. Journal of Colloid and Interface Science. 1968;26:62–69.
28. Choi JH, Kang SR, Kim H, et al. Dye-doped silica nanoparticle with HIV-1 TAT peptide for bioimaging. J Biomed Nanotechnol. 2013; 9(2):291–294.
29. Jalalian SH, Taghdisi SM, Shahidi Hamedani N, et al. Epirubicin loaded super paramagnetic iron oxide nanoparticle-aptamer bioconjugate for combined colon cancer therapy and imaging in vivo. Eur J Pharm Sci. 2013;50(2):191–197.
30. Ruoslahti E, Bhatia SN, Sailor MJ. Targeting of drugs and nanoparticles to tumors. J Cell Biol. 2010;188(6):759–768.
31. Zhou J, Shi J, Hou J, et al. Phosphatidylserine exposure and proco-agulant activity in acute promyelocytic leukemia. J Thromb Haemost. 2010;8(4):773–782.
32. Ren SX, Shen J, Cheng AS, et al. FK-16 derived from the anticancer peptide LL-37 induces caspase-independent apoptosis and autophagic cell death in colon cancer cells. PLoS One. 2013;8(5):e63641.
33. Zhu XM, Wang YX, Leung KC, et al. Enhanced cellular uptake of aminosilane-coated superparamagnetic iron oxide nanoparticles in mammalian cell lines. Int J Nanomedicine. 2012;7:953–964.
34. Kocbek P, Kralj S, Kreft ME, Kristl J. Targeting intracellular compartments by magnetic polymeric nanoparticles. Eur J Pharm Sci. 2013; 50(1):130–138.
35. Lerch S, Dass M, Musyanovych A, Landfester K, Mailänder V. Polymeric nanoparticles of different sizes overcome the cell membrane barrier. Eur J Pharm Biopharm. 2013;84(2):265–274.
36. Ma P, Dong X, Swadley CL, et al. Development of idarubicin and doxorubicin solid lipid nanoparticles to overcome Pgp-mediated multiple drug resistance in leukemia. J Biomed Nanotechnol. 2009;5(2):151–161.
37. Gunduz U, Keskin T, Tansık G, et al. Idarubicin-loaded folic acid conjugated magnetic nanoparticles as a targetable drug delivery system for breast cancer. Biomed Pharmacother. 2014;68(6):729–736.
38. Wang J, Chen B, Chen J, et al. Synthesis and antitumor effcacy of daunorubicin-loaded magnetic nanoparticles. Int J Nanomedicine. 2011; 6:203–211.
39. Wu KC, Yamauchi Y, Hong CY, et al. Biocompatible, surface func-tionalized mesoporous titania nanoparticles for intracellular imaging and anticancer drug delivery. Chem Commun (Camb). 2011; 47(18):5232–5234.